Director Hayden bought a large $1.06M block on Jul 30, lifting his stake 34%, and current price is actually 2.2% below where he bought — decent entry with RSI ~30 after a 37% drawdown. But this is director-only with zero C-suite, and fundamentals are weak: revenue down 40.7% YoY, negative gross margin, unprofitable, debt slightly exceeds cash. Healthcare sector is beating SPY by 8.3%, but the size